Citadel Advisors’s ACELYRIN SLRN Stock Holding History

Citadel Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,800	Closed	-$21.4K	–	15477
2024 Q4	$21.4K	Sell	6,800 -7,600	-53%	-$36.8K	﹤0.01%	13138
2024 Q3	$71K	Buy	14,400 +9,800	+213%	+$50.6K	﹤0.01%	11539
2024 Q2	$20.3K	Sell	4,600 -8,700	-65%	-$40.8K	﹤0.01%	12628
2024 Q1	$89.8K	Sell	13,300 -79,000	-86%	-$600K	﹤0.01%	11501
2023 Q4	$689K	Buy	92,300 +33,100	+56%	+$283K	﹤0.01%	7425
2023 Q3	$602K	Buy	59,200 +57,500	+3,382%	+$1.22M	﹤0.01%	7658
2023 Q2	$35.5K	Buy	+1,700	New	+$34.8K	﹤0.01%	12176

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's SLRN Position: Q2 2025 in Review

Citadel Advisors sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 176,437 shares — an estimated $436K sold.

Citadel Advisors first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $121M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Citadel Advisors reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 176,437 ACELYRIN shares in Q2 2025, an estimated $436K.
Citadel Advisors first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Citadel Advisors's ACELYRIN position peaked at $121M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.